Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will ...
Epilepsy Surgery Market Poised for Steady Growth Driven by Advancements in Surgical Procedures and Rising Prevalence of Epilepsy.Pune, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Epilepsy Surgery Market Size & ...
J Midwifery Womens Health. 2008;53(4):289-301. Because employment and schooling may be profoundly affected for persons with CFS, it is important to realize that the disorder is a disabling ...
Penn working to minimize 'consequences' of potential $240M in NIH cuts © 2025 American City Business Journals. All rights reserved. Use of and/or registration on any ...
Other companies that have developed FLT3 inhibitors for AML include Cephalon (now part of Teva) - which reported disappointing data with its lestaurtinib candidate a couple of years ago ...
Other frequent patentees included Takeda, Cephalon, Roche, and Abbott Labs. On the defence side, the report identified Sandoz as the most frequent participant, with 422 cases as a defendant.
After hours: February 13 at 4:20:00 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback